topotecan has been researched along with Bone Marrow Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Deméocq, F; Halle, P; Isfan, F; Kanold, J; Kelly, A; Lang, P; Marabelle, A; Merlin, E; Paillard, C; Rochette, E; Tchirkov, A | 1 |
Cheshire, PJ; Houghton, JA; Houghton, PJ; Luo, X; Poquette, C; Richmond, LB; Santana, VM; Stewart, CF; Thompson, J; Zamboni, WC | 1 |
2 other study(ies) available for topotecan and Bone Marrow Neoplasms
Article | Year |
---|---|
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Bone Marrow Neoplasms; Bone Neoplasms; Child; Combined Modality Therapy; Dacarbazine; Doublecortin Domain Proteins; Haplotypes; Hematopoietic Stem Cell Transplantation; Homeodomain Proteins; Humans; Immunotherapy; Interleukin-2; Killer Cells, Natural; Male; Microtubule-Associated Proteins; Neoplasm, Residual; Neuroblastoma; Neuropeptides; Remission Induction; Temozolomide; Topotecan; Transcription Factors; Transplantation, Homologous; Tyrosine 3-Monooxygenase | 2012 |
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Marrow Neoplasms; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mice; Mice, Inbred CBA; Neuroblastoma; Retroperitoneal Space; Rhabdomyosarcoma; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous | 1998 |